Open Call for Innovative Defense-Related Dual-Purpose Technologies/Solutions with a Clear Air Force Stakeholder Need

Neurovation Labs (NL) is a biotechnology company revolutionizing the way PTSD is diagnosed and treated. NL’s first product is an objective diagnostic tracer for use in brain imaging. The tracer, 18F-NVL-1, is designed to target the first brain biomarker of PTSD, discovered by co-founders Drs. Perusini and Fanselow to be a biologial cause of the disorder. NL’s second product is a companion PTSD treatment for PTSD. The targeted medication will be optimized to inhibit the same biomarker, getting at the cause and not just acting as a symptom masker. PTSD is a serious mental health condition characterized by debilitating symptoms that interfere with daily life. The current ineffective diagnostic and treatment options overwhelm healthcare and cause a huge economic burden. NL is leveraging its biomarker discovery to develop commercializable products that have the potential to not only detect PTSD almost immediately following a trauma, but also effectively cure the disorder, ending the current PTSD epidemic among servicemembers as we know it. NL’s dual solution to PTSD may provide great value not just to the DoD but also to the large suffering civilian population, and we can start to diagnose mental health disorders with the same precision as we do cancer.